EA201201446A1 - Пептидные производные, их получение и применение - Google Patents

Пептидные производные, их получение и применение

Info

Publication number
EA201201446A1
EA201201446A1 EA201201446A EA201201446A EA201201446A1 EA 201201446 A1 EA201201446 A1 EA 201201446A1 EA 201201446 A EA201201446 A EA 201201446A EA 201201446 A EA201201446 A EA 201201446A EA 201201446 A1 EA201201446 A1 EA 201201446A1
Authority
EA
Eurasian Patent Office
Prior art keywords
interest
peptide derivatives
production
application
user
Prior art date
Application number
EA201201446A
Other languages
English (en)
Other versions
EA022422B1 (ru
Inventor
Патрик Влэг
Марион Давид
Ив Молино
Мишель Крещатиски
Original Assignee
Вект-Орус
Сантр Насьональ Де Ля Решерш Сьентифик
Юниверситэ Де Ля Медитерранэ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вект-Орус, Сантр Насьональ Де Ля Решерш Сьентифик, Юниверситэ Де Ля Медитерранэ filed Critical Вект-Орус
Publication of EA201201446A1 publication Critical patent/EA201201446A1/ru
Publication of EA022422B1 publication Critical patent/EA022422B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение относится к пептидным производным (пептидам и псевдопептидам) и их применению в качестве векторов для веществ, представляющих интерес для пользователя. Изобретение также относится к конъюгатам, содержащим пептидное производное по изобретению, соединенное с веществом, представляющим интерес для пользователя. Пептиды по изобретению можно применять для векторного переноса в форме конъюгатов, как правило, предшественников ("пролекарств") тех веществ, которые представляют фармацевтический или диагностический интерес, например, терапевтических, визуализирующих или диагностических агентов или молекулярных зондов через клеточные мембраны, в особенности с целью способствовать их переносу через гематоэнцефалический барьер.
EA201201446A 2010-04-21 2011-04-18 Пептидные производные, их получение и применение EA022422B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1053036A FR2959229B1 (fr) 2010-04-21 2010-04-21 Derives peptidiques, leur preparation et leurs utilisations
PCT/FR2011/050883 WO2011131896A2 (fr) 2010-04-21 2011-04-18 Derives peptidiques, leur preparation et leurs utilisations comme vecteurs

Publications (2)

Publication Number Publication Date
EA201201446A1 true EA201201446A1 (ru) 2013-04-30
EA022422B1 EA022422B1 (ru) 2015-12-30

Family

ID=43365640

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201446A EA022422B1 (ru) 2010-04-21 2011-04-18 Пептидные производные, их получение и применение

Country Status (15)

Country Link
US (1) US8877716B2 (ru)
EP (1) EP2547692B1 (ru)
JP (1) JP6073779B2 (ru)
CN (1) CN103119052B (ru)
AU (1) AU2011244107B2 (ru)
BR (1) BR112012027043B1 (ru)
CA (1) CA2796174C (ru)
DK (2) DK2547692T5 (ru)
EA (1) EA022422B1 (ru)
ES (2) ES2637265T3 (ru)
FR (1) FR2959229B1 (ru)
HU (2) HUE035416T2 (ru)
PL (1) PL2547692T3 (ru)
TR (1) TR201905058T4 (ru)
WO (1) WO2011131896A2 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1463512B1 (en) 2002-01-11 2014-05-28 biOasis Technologies Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
WO2014060601A1 (en) 2012-10-19 2014-04-24 Vect-Horus Compositions and methods for drug delivery
FR2959229B1 (fr) 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
WO2012105224A1 (ja) * 2011-01-31 2012-08-09 オリンパス株式会社 ワクチン・アジュバント
WO2013006706A1 (en) 2011-07-05 2013-01-10 Bioasis Technologies Inc. P97-antibody conjugates and methods of use
AU2013296557B2 (en) 2012-07-31 2019-04-18 Bioasis Technologies Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
EP2970433B1 (en) 2013-03-13 2019-09-18 Bioasis Technologies Inc. Fragments of p97 and uses thereof
CN104117069A (zh) * 2013-04-26 2014-10-29 复旦大学 一种针对脑胶质瘤的靶向纳米递药系统及其制备方法和应用
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
EP2896402A1 (en) 2014-01-20 2015-07-22 Vect-Horus Activated neurotensin molecules and the uses thereof
EP3102608B1 (en) 2014-02-03 2019-09-18 Bioasis Technologies Inc. P97 fusion proteins
US10392605B2 (en) 2014-02-19 2019-08-27 Bioasis Technologies Inc. P97-IDS fusion proteins
CN106413757B (zh) 2014-05-01 2022-01-14 比奥阿赛斯技术有限公司 p97-多核苷酸结合物
US20160215031A1 (en) * 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US20190085093A1 (en) * 2015-11-17 2019-03-21 Seoul National University R&Db Foundation Composition for regulating cell division comprising fcho1 modulator, and method for regulating cell division using same
JP7037201B2 (ja) * 2016-09-13 2022-03-16 アンジオクライン・バイオサイエンス・インコーポレイテッド 改変内皮細胞を含む血液脳関門
WO2018118015A1 (en) 2016-12-19 2018-06-28 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
AU2018211539B2 (en) * 2017-01-30 2021-10-28 Centre National De La Recherche Scientifique Compositions and methods for cancer imaging and radiotherapy
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
WO2019221576A1 (ko) * 2018-05-17 2019-11-21 광주과학기술원 Ccn5를 유효성분으로 포함하는 망막질환 예방 또는 치료용 약학 조성물
CA3124790A1 (en) 2019-01-09 2020-07-16 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047566A1 (en) 1998-03-17 1999-09-23 The Uab Research Foundation Synthetic peptides that enhance ldl uptake
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
AU2001255524A1 (en) * 2000-04-21 2001-11-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
CN1388131A (zh) * 2002-06-10 2003-01-01 牛勃 系列新型药物载体、新型载体－酪氨酸羟化酶融合蛋白及其制备
AU2003286870A1 (en) * 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
AR053269A1 (es) * 2005-05-16 2007-04-25 Monsanto Technology Llc Plantas y semillas de maiz con mejoramiento de asparagina y proteina
CN101490270A (zh) * 2005-07-19 2009-07-22 伊利诺斯大学理事会 用于穿越血脑屏障并进入脑部癌细胞的转运剂及其使用方法
FR2889532B1 (fr) 2005-08-03 2007-10-12 Lab Francais Du Fractionnement Anticorps diriges contre le recepteur du ldl
FR2937322B1 (fr) * 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
FR2959229B1 (fr) 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations

Also Published As

Publication number Publication date
EP2547692B1 (fr) 2017-05-17
FR2959229B1 (fr) 2013-01-18
HUE035416T2 (en) 2018-05-02
JP6073779B2 (ja) 2017-02-01
US20130108548A1 (en) 2013-05-02
PL2547692T3 (pl) 2018-08-31
DK2547692T3 (en) 2017-09-04
EA022422B1 (ru) 2015-12-30
BR112012027043A2 (pt) 2016-12-06
AU2011244107A1 (en) 2012-11-08
JP2013525336A (ja) 2013-06-20
CA2796174C (en) 2018-07-17
TR201905058T4 (tr) 2019-05-21
DK2547692T5 (en) 2017-09-25
EP2547692A2 (fr) 2013-01-23
DK2908837T3 (en) 2019-04-23
WO2011131896A2 (fr) 2011-10-27
ES2719727T3 (es) 2019-07-12
CN103119052A (zh) 2013-05-22
CN103119052B (zh) 2016-06-01
BR112012027043B1 (pt) 2022-03-22
FR2959229A1 (fr) 2011-10-28
WO2011131896A3 (fr) 2012-01-19
ES2637265T3 (es) 2017-10-11
US8877716B2 (en) 2014-11-04
HUE042850T2 (hu) 2019-07-29
CA2796174A1 (en) 2011-10-27
AU2011244107B2 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
EA201201446A1 (ru) Пептидные производные, их получение и применение
EA201170587A1 (ru) Пептидные производные и их применение в качестве векторов молекул в форме конъюгатов
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
WO2012158962A3 (en) Improved peptide pharmaceuticals
MX2018013981A (es) Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina.
MX362432B (es) Variantes de oxm pegilada.
MX344219B (es) Productos farmaceuticos peptidicos mejorados para resistencia a insulina.
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
WO2008137758A3 (en) Amino acid lipids and uses thereof
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
MX338914B (es) Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos.
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
BR112012017556A2 (pt) formulações de torta liofilizada
TR200806298A2 (tr) Farmasötik formülasyon
Domalaon et al. Dilipid ultrashort cationic lipopeptides as adjuvants for chloramphenicol and other conventional antibiotics against Gram-negative bacteria
CY1115961T1 (el) Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate)
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
IN2014DN03213A (ru)
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
WO2010052243A3 (en) Neurotensin-derived branched peptides and uses thereof
MX365599B (es) Moleculas de transporte especificas de proteoglicano c4s.
WO2009111273A3 (en) Peptide targeting imaging agents and methods of use thereof
BRPI0916895A2 (pt) uso de lisina, arginina e outros compostos aminados, produto e administração de dosagem de produto

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ TM